Activated protein C and the ovarian hyperstimulation syndrome: possible therapeutic implications
- PMID:16434147
- DOI: 10.1016/j.mehy.2005.08.058
Activated protein C and the ovarian hyperstimulation syndrome: possible therapeutic implications
Abstract
Given the efficacy and safety of recombinant human activated protein C (rhAPC) in the systemic inflammatory response syndrome (SIRS), this study was designed to review the evidence for rhAPC as a possible therapeutic option in the treatment of severe ovarian hyperstimulation syndrome (OHSS). SIRS, like OHSS, is a proinflammatory and prothrombotic disorder whose cornerstone is endothelial dysfunction in which protein C deficiency is a frequent occurrence. Recently, the use of rhAPC has been shown to be of benefit with a reduction in mortality and an improvement in indicators of inflammation and coagulation. OHSS is typically an iatrogenic disorder resulting from ovarian stimulation as a component of infertility treatment. The pathogenesis of OHSS, like sepsis, is related to endothelial dysfunction and inflammation and can result in significant morbidity including end organ hypoperfusion, disseminated intravascular coagulation (DIC), thrombosis, and occasionally, death. We have performed a review of the literature to identify similarities between these disease processes to develop a theoretical basis for the use of rhAPC in patients with moderate to severe OHSS. Use of rhAPC in this group may attenuate the disease process and reduce the potential morbidity associated with this iatrogenic disorder.
Similar articles
- Use of recombinant human activated protein C in treatment of severe sepsis in a pregnant patient with fully symptomatic ovarian hyperstimulation syndrome.Mikaszewska-Sokolewicz M, Mayzner-Zawadzka E.Mikaszewska-Sokolewicz M, et al.Med Sci Monit. 2005 Jun;11(6):CS27-32. Epub 2005 May 25.Med Sci Monit. 2005.PMID:15917724
- Review of the evidence base of strategies to prevent ovarian hyperstimulation syndrome.Mathur R, Kailasam C, Jenkins J.Mathur R, et al.Hum Fertil (Camb). 2007 Jun;10(2):75-85. doi: 10.1080/14647270601111239.Hum Fertil (Camb). 2007.PMID:17564886Review.
- Recombinant activated protein C: the key is clinical assessment of risk of death, not subset analysis.Dellinger RP.Dellinger RP.Crit Care. 2006 Feb;10(1):114. doi: 10.1186/cc3991.Crit Care. 2006.PMID:16542472Free PMC article.Review.
- Recombinant activated protein C attenuates endothelial injury and inhibits procoagulant microparticles release in baboon heatstroke.Bouchama A, Kunzelmann C, Dehbi M, Kwaasi A, Eldali A, Zobairi F, Freyssinet JM, de Prost D.Bouchama A, et al.Arterioscler Thromb Vasc Biol. 2008 Jul;28(7):1318-25. doi: 10.1161/ATVBAHA.107.161737. Epub 2008 May 1.Arterioscler Thromb Vasc Biol. 2008.PMID:18451327
- Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever.Hensley LE, Stevens EL, Yan SB, Geisbert JB, Macias WL, Larsen T, Daddario-DiCaprio KM, Cassell GH, Jahrling PB, Geisbert TW.Hensley LE, et al.J Infect Dis. 2007 Nov 15;196 Suppl 2:S390-9. doi: 10.1086/520598.J Infect Dis. 2007.PMID:17940975
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources